Skip to main content

Table 2 Demographics in European series on EGFR mutations testing

From: Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

Series Year Origin N Stages Further description
Cortes-Funes et al. [10] 2005 Spain 83 Advanced Failing 1st line/TKI therapy
Marchetti et al. [15] 2005 Italy 860 Stage I-II-III Resection specimen
Rosell et al. [19] 2009 Spain 2105 Advanced -
Penzel et al. [21] 2011 Germany 1047 All -
Helland et al. [16] 2011 Norway 240 Stage I-II-III Resection specimen
Vincenten et al. [20] 2012 Netherlands 810 All -
Smits et al. [14] 2012 Netherlands 778 Advanced -
Leary et al. [12] 2012 England 144 All -
Pennycuick et al. [11] 2012 England 215 All Non-squamous NSCLC
Vaguliene et al. [13] 2012 Lithuania 103 Advanced Non-squamous NSCLC
Cadranel et al. [22] 2012 France 522 All Failing 1st line/TKI therapy
This series 2012 Belgium 297 Advanced ESMO guideline selected
  1. N: number; TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; ESMO: European Society of Medical Oncology.